SYSTEMIC, ALLOGENIC STEM CELL THERAPIES FOR TREATMENT OF DISEASES IN EQUINES

1 . A method for treating an equine patient suffering from a disease or diseased state, comprising the step of administering a therapeutic dose of a mesenchymal stem cell composition through an intravenous injection, the mesenchymal stem cell composition comprising mesenchymal stem cells harvested from at least one tissue selected from the group consisting of: placental tissue, uterine tissue, bone marrow, dental tissue, testicular tissue, umbilical cord tissue, and skin tissue.

2 . The method of claim 1 , wherein the therapeutic dose is about 6 million mesenchymal stem cells per kg of the patient's body weight.

3 . The method of claim 2 , wherein the therapeutic dose does not exceed about 50 million mesenchymal stem cells regardless of the patient's body weight.

4 . The method of claim 1 , wherein the mesenchymal stem cells are autologous to the patient.

5 . The method of claim 1 , wherein the mesenchymal stem cells are allogeneic to the patient.

6 . The method of claim 1 , wherein the mesenchymal stem cell composition consists essentially of mesenchymal stem cells and saline.

7 . The method of claim 1 , wherein the mesenchymal stem cell composition includes mesenchymal stem cells and saline at a concentration of no more than 500,000 cells per mL.

8 . The method of claim 1 , wherein the mesenchymal stem cell composition includes mesenchymal stem cells and saline at a concentration of no more than 100,000 cells per mL.

9 . The method of claim 1 , wherein the mesenchymal stem cell composition further comprises factors from a stem cell conditioned media

10 . The method of claim 1 , wherein the disease or diseased state is exercise-induced pulmonary edema.

11 . The method of claim 1 , wherein the disease or diseased state is exercise-induced pulmonary hemorrhage.

12 . The method of claim 1 , wherein the disease or diseased state is recurrent airway obstruction.

13 . The method of claim 1 , wherein the disease or diseased state is pleuritis.

14 . The method of claim 1 , wherein the disease or diseased state is exertional rhabdomyolysis.

15 . The method of claim 1 , wherein the disease or diseased state is dorsal displacement.

16 . The method of claim 1 , wherein the disease or diseased state is selected from the group consisting of: degenerative bone disease, osteoarthritis, rheumatoid arthritis, polyarthritis, systemic lupus erythematosus, inflammatory bowel disease, atopy, hepatitis, steroid responsive meningitis-arteritis, beagle pain syndrome, degenerative myelopathy, chronic renal failure disease, dilated and mitral cardiomyopathy, keratoconjunctivitis sicca, immune mediated non-erosive arthritis, immune mediated hemolytic anemia, immune mediated thrombocytopenia, Evans syndrome, intervertebral disc disease, muscle fibrosis secondary to disease or trauma, refractory corneal ulcer, diabetes mellitus, spinal trauma, eosinophilic granuloma complex, hypertrophic cardiomyopathy, cholangitis, spinal injury, rhabdomyolysis, corneal ulcer, eczema, multiple sclerosis, muscular dystrophy, myocardial infarction, and congestive heart failure.

17 . A mesenchymal stem cell composition comprising:

a. at least 6 million equine mesenchymal stem cells derived from progenitor cells harvested from placental tissue, bone marrow, dental tissue, testicle tissue, uterine tissue, umbilical cord tissue, or skin tissue; and

b. a saline solution, wherein the composition has a maximum concentration of about 500,000 cells per mL.